Eocene Ltd. Ordinary Shares

EOCN

市值 US$304萬

Standby Equity Purchase Agreement (SEPA) with YA II PN, LTD. (Yorkville) will be terminated effective immediately The Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) and will continue to be listed and traded on the Nasdaq Capital Market under the new ticker symbol RAMAT-GAN, Israel, Sept.

The prospective, single-arm study enrolled 32 colorectal cancer patients at three leading clinical centers in Israel. The primary objective was to demonstrate feasibility of intraoperative quantitative measurement of colon tissue quality.

Xtandi® (enzalutamide) is indicated as monotherapy for the treatment of patients with non-metastatic prostate cancer (nmCSPC) at high risk of metastasis and for the treatment of patients with metastatic prostate cancer (mCSPC) who are maintaining treatment with a GnRH analogue. Global sales for Xtandi® (marketed by Astellas Pharma and Pfizer) reached approximately $8 billion and $6 billion globally in 2024 and 2025, respectively.

Aramchol meglumine is the only SCD1 inhibitor with an established clinical safety profile and confirmed blood-brain barrier (BBB) penetration. In order to improve patient convenience and long-term treatment adherence by Parkinson patients affected by dysphagia, an ODF formulation was developed demonstrating ~150% higher systemic bioavailability and ~300% significant increase in CNS exposure than conventional oral administration.

Galmed has developed, in collaboration with Barcode Nanotech, a unique proprietary lipid nanoparticles (LPNs) novel formulation of Aramchol that penetrates the heart tissue and redirects Aramchol's biodistribution away from liver-hepatocytes to the heart's muscle. Cardiac fibrosis is a major driver of chronic heart failure, the leading cause of death globally, responsible for an estimated 20.5 million deaths in 2025.

Colospan Ltd. ("Colospan") provides Galmed Pharmaceuticals Ltd.

Transaction will add FDA Breakthrough Device-Designated technology with active U.S. pivotal IDE trial, positioning Galmed to address one of colorectal surgery's most serious unmet needs. Colospan's CG-100 Intraluminal Bypass Device, is CE marked under EU's Medical Device Regulation ("MDR") and ready for commercial launch in the EU and Israel.

- Tissue Dynamics identified a previously unrecognized metabolic mechanism driving cardiac fibrosis using a human cardiac organoid model, revealing disease biology that is not accessible through conventional animal models. - In inflammatory human cardiac organoids, the combination of Aramchol Meglumine and a selective PPARα agonist reduced fibrotic burden by approximately 4-fold (p

Results from Study AM-001 mark a pivotal advance through the transition to a once daily lower 400mg dose of AM enabling: Production of GMP clinical batch for Galmed's upcoming clinical trials Solidification and prolongation of Aramchol's IP protection Potential reduction in drug CoGs by ~50% Improvement in patients' convenience and compliance upon potential commercialization RAMAT-GAN, Israel, May 14, 2026 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver disease and GI oncological therapeutics, announced today major milestone results from a Phase 1 PK study in healthy subjects (Study AM-001).

Novel vascularized, sensor-embedded cardiac organoid model will focus on chronic post-MI remodeling and HFpEF, linking lipid metabolism, SCD1 activity, fibrosis, and impaired tissue repair REHOVOT, Israel and RAMAT-GAN, Israel, May 6, 2026 /PRNewswire/ -- Tissue Dynamics Ltd. and Galmed Pharmaceuticals Ltd.